Stuttgart
24.04.26 | 21:46
6,000 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,150 | 6,200 | 25.04. | |
| 6,000 | 6,300 | 24.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.04. | Mizuho reiterates Relmada stock rating on Phase 3 trial progress | 10 | Investing.com | ||
| 25.03. | Analyse von Relmada: Wie die Fair-Value-Methode einen Kursgewinn von 65 % identifizierte | 3 | Investing.com Deutsch | ||
| 24.03. | Relmada wins bullish view at Piper Sandler on cancer therapy | 3 | Seeking Alpha | ||
| RELMADA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 24.03. | Relmada Therapeutics stock initiated at Overweight by Piper Sandler | 3 | Investing.com | ||
| 24.03. | Piper Sandler startet Coverage für Relmada Therapeutics mit "Overweight" | 1 | Investing.com Deutsch | ||
| 20.03. | RELMADA THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Relmada Therapeutics verfehlt Gewinnprognose für Q4 2025, Aktie zeigt sich dennoch stabil | 2 | Investing.com Deutsch | ||
| 19.03. | RELMADA THERAPEUTICS, INC. - 10-K, Annual Report | 1 | SEC Filings | ||
| 19.03. | Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update | 139 | GlobeNewswire (Europe) | Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with favorable... ► Artikel lesen | |
| 13.03. | Relmada: Positive Studiendaten stützen Kaufempfehlung von Mizuho | 2 | Investing.com Deutsch | ||
| 13.03. | Mizuho reiterates Relmada stock rating on positive cancer trial data | 3 | Investing.com | ||
| 12.03. | RLMD Stock Surges 42% in a Week: Here's What You Should Know | 1 | Zacks | ||
| 12.03. | Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026 | 1 | GlobeNewswire (USA) | ||
| 10.03. | Relmada Therapeutics auf der Leerink Global: Strategischer Schwenk zur Uro-Onkologie | 2 | Investing.com Deutsch | ||
| 09.03. | Relmada Therapeutics Reports Positive 12-Month Phase 2 Data For NDV-01 In Bladder Cancer | 5 | RTTNews | ||
| 09.03. | Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday | 2 | Benzinga.com | ||
| 09.03. | Mizuho reiterates Relmada stock rating on bladder cancer trial data | 4 | Investing.com | ||
| 09.03. | Why Is Relmada Therapeutics Stock Soaring Monday? | 8 | Benzinga.com | ||
| 09.03. | Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing | 14 | GlobeNewswire (USA) | ||
| 09.03. | Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer | 159 | GlobeNewswire (Europe) | Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any time Tolerability... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,15 | +0,22 % | Insiderverkäufe, Kaufempfehlungen und KI-Fantasie: BioNTech, Evotec, Vidac Pharma Aktie. | Insiderverkäufe bei Vidac Pharma. Dies ist jedoch kein Alarmsignal, sondern bietet eher eine Einstiegschance. Das Unternehmen arbeitet an einer revolutionären Krebstherapie. In 2026 sollen wichtige... ► Artikel lesen | |
| EVOTEC | 5,350 | -0,93 % | Evotec: Gewinnmitnahme! | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| MODERNA | 43,480 | +0,49 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| VALNEVA | 2,326 | -0,60 % | Valneva vor kritischer Marke: Droht jetzt der nächste große Absturz? - Was sich am Wochenende verändert hat | ||
| AMGEN | 295,40 | +0,44 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| NOVAVAX | 6,960 | -0,85 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOGEN | 156,62 | -0,43 % | Biogen To Acquire TJ Bio's Rights To Felzartamab In The Greater China Region | WESTON (dpa-AFX) - Biogen Inc. (BIIB) and TJ Biopharma have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio's exclusive rights to felzartamab in the Greater... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,740 | +1,86 % | HEIDELBERG PHARMA AG - Ruhe vor dem nächsten Impuls | ||
| ILLUMINA | 109,30 | +0,15 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 43,400 | +4,25 % | CRISPR Therapeutics Has Major Catalysts Ahead. Is This Biotech Stock a Screaming Buy? | ||
| NANOREPRO | 1,485 | -3,26 % | From tests to brands, revamping NanoRepro; INITIATE with BUY: NanoRepro transforms into a multi-brand ... | No longer a mere self-test company, NanoRepro has used the pandemic windfall from COVID tests and transformed itself into a multi-brand consumer health platform. The company has acquired stakes in complementary... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| OCUGEN | 1,414 | -0,56 % | OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead | ||
| INOVIO PHARMACEUTICALS | 1,008 | +3,12 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen |
RELMADA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 6,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RELMADA THERAPEUTICS INC finden Sie auf Wallstreet Online.